Salt and blood pressure in children

Alderman, Michael H.

doi:10.1038/sj.jhh.1002269

Cited by 2 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, a larger prospective, interventional study demonstrated that the combination of blood testing with PET-CT could be used to screen for lung cancer [22]. Therefore, the combination of cfDNA and metabolic tumor burden was performed to distinguish NSCLC from tuberculosis.…”

Section: Discussionmentioning

confidence: 99%

“…However, PET-CT shows low speci city for differential diagnosis of NSCLC from tuberculosis, due to the tuberculosis site also presents an elevated level of glucose consumption [20,21]. Of note, recently, a larger prospective, interventional study demonstrated that the combination of cancer blood testing with PET-CT was feasible to screen for multi-cancer and guide intervention [22].…”

mentioning

confidence: 99%

See 1 more Smart Citation

Combination of Circulating Cell-Free DNA and Metabolic Tumor Burden to Distinguish Non-Small Cell Lung Cancer from Tuberculosis

Zheng

Zhang

Quan

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Non-small cell lung (NSCLC) holds high mortality owing to the difficulty to early detection from other lung mass, such as tuberculosis. This study evaluates the clinical value of the combination of circulating cell-free DNA (cfDNA) quantification and metabolic tumor burden to distinguish NSCLC from tuberculosis. Methods: A total of 149 NSCLC patients, 151 tuberculosis patients and 150 healthy controls were included. Quantifying serum cfDNA fragments from ALU (115 bp) gene by RT-PCR. Metabolic tumor burden (SUV-Maxa) values were detected by preoperative the 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET/CT). A549 cell, NCI–H460 cell, NSCLC and tuberculosis mice model were used to elucidate the specific mechanism. Results: Serum cfDNA levels and SUV-Maxa were higher in NSCLC patients than those in healthy controls and those in tuberculosis. Meanwhile, mice models showed the similar discovery. In addition, obvious correlations of cfDNA and metabolic tumor burden were only existed in NSCLC patients and mice model, rather than tuberculosis and control. Moreover, the combination of cfDNA and metabolic tumor burden displayed better effect to distinguish NSCLC from tuberculosis than alone use. Mechanistically, upregulated Glucose transporter 1 (GLU1) increased necroptosis-induce cfDNA rise by FasL/caspase 8/caspase 3 pathway and promoted metabolic tumor burden in NSCLC. Conclusions: The combination of cfDNA and metabolic tumor burden displayed better effect to distinguish NSCLC from tuberculosis, owing to upregulated GLU1 increased cfDNA levels by FasL/caspase 8/caspase 3 pathways and promoted metabolic tumor burden in NSCLC.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Combination of Circulating Cell-Free DNA and Metabolic Tumor Burden to Distinguish Non-Small Cell Lung Cancer from Tuberculosis

Zheng

Zhang

Quan

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…1 The major message of this meta-analysis was the difficulty for individuals to reduce salt intake over a long period of time, in countries where E80% of salt is already in the food. 8 In fact, Hopper et al 7 do show that even with a small reduction in salt intake, there was still a significant fall in BP.…”

mentioning

confidence: 99%